• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Neurology

Moderate to severe TBI is associated with elevated malignant brain tumor risk

byJayden BerdugoandSimon Pan
January 13, 2026
in Neurology, Oncology
Reading Time: 3 mins read
Brain lesions on MRI linked with subsequent increased stroke risk
Share on FacebookShare on Twitter

1. In this retrospective cohort study, moderate to severe traumatic brain injury (TBI) was associated with an increased risk of malignant brain tumour development compared to mild TBI and no TBI.

2. Among the TBI group, a larger number of individuals had a mild TBI compared to a moderate to severe TBI.

Evidence Rating Level: 2 (Good) 

Study Rundown: Traumatic Brain Injury (TBI) has substantial prevalence among the general population and results in increased morbidity and mortality, though the mechanism is not fully understood. Brain tumors, though only confirmed to have an increased risk through ionizing radiation, have shown a potential link through TBI. Studies of military populations, a population with high TBI prevalence, have been limited by confounding factors. To shed some light on inconclusive population studies and to increase early detection of brain tumors, this study investigated whether a link between TBI and malignant brain tumors could be established. This retrospective cohort study used data from US adult civilians across a variety of trauma centres, using codes from the Centers for Disease Control and Prevention for TBI and malignant tumors. Among the exposure group, the majority of the participants had a mild TBI compared to a moderate to severe TBI. Furthermore, there was a larger number of participants in the moderate to severe TBI group who developed a malignant brain tumor compared to the mild TBI group and the control group. One limitation of the study was the inability to determine the specific types of malignant brain tumor associated with TBI. Despite this, the study found that a history of moderate to severe TBI was associated with a future risk of malignant brain tumor development. These results indicate that adults with a history of moderate to severe TBI may benefit from enhanced monitoring and follow-up to identify potential development of malignant brain tumors. To tackle the limitations of this study, future research into screening programs for TBI patients is recommended.

Click here to read the study in JAMA Network Open

Relevant Reading: Traumatic Brain Injury and Subsequent Risk of Brain Cancer in US Veterans of the Iraq and Afghanistan Wars

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

Borderline-low hemoglobin levels linked to increased mortality

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

In-Depth [retrospective cohort study]: This retrospective cohort study was conducted on 151,358 individuals, split into two equal cohorts of 75,679 participants per group. Participants were included if they were aged 18 years or older and had two or more visits for TBI. Inclusion in the study was limited to a 1-year observation period and a history of prior radiation exposure. Among the Mass General Brigham (MGB) group, the median follow-up time was 7.2 (IQR, 4.1-10.1) years. In the TBI group, 80.3% of participants had mild TBI, and 19.7% had moderate to severe TBI. the incidence of malignant brain tumors was greater in individuals with moderate to severe TBI (87 [0.6%]) compared to those with mild TBI (222 [0.4%]) and the control group (314 [0.4%]) (P=.001). Among matched individuals, the moderate to severe TBI group had a higher rate of malignant brain tumors (87 [0.6%]) compared to the control group (64 [0.4%]) (P=.003). In the regression analysis, individuals with moderate to severe TBI had a significantly higher risk of developing malignant brain tumors (HR, 1.67; 95% CI, 1.31-2.12; P<.001) compared with those with mild TBI (HR, 0.99; 95% CI, 0.83-1.18), independent of confounding factors. Overall, these findings support the need for ongoing monitoring of individuals with moderate to severe TBI to help with earlier detection of malignant brain tumors. 

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancercancer detectionneurologyoncologytbi
Previous Post

2 Minute Medicine Rewind September 1, 2025

Next Post

Personalized risk messages may not increase colorectal cancer screening uptake

RelatedReports

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Next Post
2 Minute Medicine Rewind October 21, 2019

Personalized risk messages may not increase colorectal cancer screening uptake

Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males

Serum albumin-to-creatinine demonstrates an inverse and non-linear relationship with the risk of non-alcoholic fatty liver disease

An absence of cardiovascular risk factors is linked to over ten additional healthy years

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.